{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:36:31Z","timestamp":1790922991699,"version":"4.1.0"},"reference-count":47,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,4,5]],"date-time":"2020-04-05T00:00:00Z","timestamp":1586044800000},"content-version":"unspecified","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"The Research Foundation of Pulmonary Diseases HES"},{"DOI":"10.13039\/501100008368","name":"Suomen Tuberkuloosin Vastustamisyhdistyksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008368","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research Foundation of North Finland"},{"DOI":"10.13039\/100010125","name":"Jalmari ja Rauha Ahokkaan S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010125","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2020,3,18]]},"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The aim of this study was to compare the clinical characteristics, causes of death and factors impacting on the prognosis of patients with idiopathic pulmonary fibrosis (IPF) and other fibrosing interstitial lung disease (FILD) with a history of acute exacerbation (AE) of IPF or FILD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Retrospective data of hospital treatment periods caused by AE-IPF and AE-FILD were collected from medical records. Clinical features and survival data of IPF and non-IPF cases were evaluated and compared. The underlying and immediate causes of death were gathered from death certificates.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 128 patients fulfilled the criteria for inclusion. IPF (n=79\/62%), rheumatoid arthritis-associated interstitial lung disease (RA-ILD; n=17\/14%) and asbestosis (n=11\/8.6%) were the most common FILD subgroups in the study. The median survival after hospitalisation in AE-IPF was 2.6 months compared with 21 months in other AE-FILDs (p&lt;0.001). The survival difference was not explained by age, gender or pulmonary function test results at the time of hospitalisation. Patients with non-specific interstitial pneumonia and RA-ILD had the most favourable prognosis. ILD was the most common underlying cause of death in both patients with IPF and with other FILD accounting for 87% and 78% of deaths, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We detected a significantly longer survival in AE of patients with non-IPF compared with that of AE-IPFs. The prognosis of patients was affected by the underlying lung disease since pulmonary fibrosis was the underlying cause of death in the majority of all patients with FILD having experienced an AE.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjresp-2020-000563","type":"journal-article","created":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T05:51:01Z","timestamp":1586238661000},"page":"e000563","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":33,"title":["Prognosis and causes of death of patients with acute exacerbation of fibrosing interstitial lung diseases"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2724-7543","authenticated-orcid":false,"given":"Johanna","family":"Salonen","sequence":"first","affiliation":[{"name":"Respiratory Medicine, Research Unit of Internal Medicine, University of Oulu, Oulu, Finland"},{"name":"Medical Research Center, Oulu University Hospital, Oulu, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna","family":"Purokivi","sequence":"additional","affiliation":[{"name":"The Center of Medicine and Clinical Research, Division of Respiratory Medicine, Kuopio University Hospital, Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risto","family":"Bloigu","sequence":"additional","affiliation":[{"name":"Medical Informatics and Statistics Research Group, University of Oulu, Oulu, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riitta","family":"Kaarteenaho","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, Research Unit of Internal Medicine, University of Oulu, Oulu, Finland"},{"name":"Medical Research Center, Oulu University Hospital, Oulu, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,4,6]]},"reference":[{"key":"2025083110412171000_7.1.e000563.1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200701-044OC"},{"key":"2025083110412171000_7.1.e000563.2","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-016-0269-2","article-title":"Variable course of disease of rheumatoid arthritis-associated usual interstitial pneumonia compared to other subtypes","volume":"16","author":"Nurmi","year":"2016","journal-title":"BMC Pulm Med"},{"key":"2025083110412171000_7.1.e000563.3","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-018-0642-4","article-title":"Underlying and immediate causes of death in patients with idiopathic pulmonary fibrosis","volume":"18","author":"K\u00e4rkk\u00e4inen","year":"2018","journal-title":"BMC Pulm Med"},{"key":"2025083110412171000_7.1.e000563.4","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-019-1022-1","article-title":"The natural history of progressive fibrosing interstitial lung diseases","volume":"20","author":"Kolb","year":"2019","journal-title":"Respir Res"},{"key":"2025083110412171000_7.1.e000563.5","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201604-0801CI"},{"key":"2025083110412171000_7.1.e000563.6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2010.01774.x"},{"key":"2025083110412171000_7.1.e000563.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2015.12.026"},{"key":"2025083110412171000_7.1.e000563.8","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.chest.2018.01.006","article-title":"Outcomes and mortality prediction model of critically ill adults with acute respiratory failure and interstitial lung disease","volume":"153","author":"Gannon","year":"2018","journal-title":"Chest"},{"key":"2025083110412171000_7.1.e000563.9","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/resp.12862","article-title":"Heterogeneity of incidence and outcome of acute exacerbation in idiopathic interstitial pneumonia","volume":"21","author":"Arai","year":"2016","journal-title":"Respirology"},{"key":"2025083110412171000_7.1.e000563.10","article-title":"Acute exacerbations of fibrotic interstitial lung diseases","volume":"27","author":"Suzuki","year":"2019","journal-title":"Respirology"},{"key":"2025083110412171000_7.1.e000563.11","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.21037\/jtd.2019.05.46","article-title":"Clinical significance of Charlson comorbidity index as a prognostic parameter for patients with acute or subacute idiopathic interstitial pneumonias and acute exacerbation of collagen vascular diseases-related interstitial pneumonia","volume":"11","author":"Murohashi","year":"2019","journal-title":"J Thorac Dis"},{"key":"2025083110412171000_7.1.e000563.12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-002971","article-title":"A cohort study of mortality predictors in patients with acute exacerbation of chronic fibrosing interstitial pneumonia","volume":"3","author":"Usui","year":"2013","journal-title":"BMJ Open"},{"key":"2025083110412171000_7.1.e000563.13","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-019-0960-1","article-title":"Acute exacerbations of fibrosing interstitial lung disease associated with connective tissue diseases: a population-based study","volume":"19","author":"Cao","year":"2019","journal-title":"BMC Pulm Med"},{"key":"2025083110412171000_7.1.e000563.14","doi-asserted-by":"crossref","DOI":"10.1177\/1479972318809476","article-title":"Differences in clinical features of acute exacerbation between connective tissue disease-associated interstitial pneumonia and idiopathic pulmonary fibrosis","volume":"16","author":"Enomoto","year":"2019","journal-title":"Chron Respir Dis"},{"key":"2025083110412171000_7.1.e000563.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908681"},{"key":"2025083110412171000_7.1.e000563.16","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0071-2018"},{"key":"2025083110412171000_7.1.e000563.17","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0050-2017"},{"key":"2025083110412171000_7.1.e000563.18","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200703-463PP"},{"key":"2025083110412171000_7.1.e000563.19","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201308-1483ST"},{"key":"2025083110412171000_7.1.e000563.20","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1255ST"},{"key":"2025083110412171000_7.1.e000563.21","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-0323"},{"key":"2025083110412171000_7.1.e000563.22","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/resp.12909","article-title":"Bronchoscopy assessment of acute respiratory failure in interstitial lung disease","volume":"22","author":"Arcadu","year":"2017","journal-title":"Respirology"},{"key":"2025083110412171000_7.1.e000563.23","first-page":"225","article-title":"Histopathological features of pulmonary asbestosis with particular emphasis on the comparison with those of usual interstitial pneumonia","volume":"43","author":"Yamamoto","year":"1997","journal-title":"Osaka City Med J"},{"key":"2025083110412171000_7.1.e000563.24","doi-asserted-by":"publisher","DOI":"10.1159\/000329891"},{"key":"2025083110412171000_7.1.e000563.25","doi-asserted-by":"crossref","DOI":"10.1186\/1465-9921-14-73","article-title":"Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials","volume":"14","author":"Collard","year":"2013","journal-title":"Respir Res"},{"key":"2025083110412171000_7.1.e000563.26","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00159709"},{"key":"2025083110412171000_7.1.e000563.27","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00115511"},{"key":"2025083110412171000_7.1.e000563.28","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00408-019-00270-z","article-title":"In-Hospital mortality in patients with idiopathic pulmonary fibrosis: a US cohort study","volume":"197","author":"Durheim","year":"2019","journal-title":"Lung"},{"key":"2025083110412171000_7.1.e000563.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2012.01.002"},{"key":"2025083110412171000_7.1.e000563.30","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00122213"},{"key":"2025083110412171000_7.1.e000563.31","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-209967"},{"key":"2025083110412171000_7.1.e000563.32","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.12659\/MSM.914725","article-title":"Independent clinical factors relevant to prognosis of patients with idiopathic pulmonary fibrosis","volume":"25","author":"Song","year":"2019","journal-title":"Med Sci Monit"},{"key":"2025083110412171000_7.1.e000563.33","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-1474"},{"key":"2025083110412171000_7.1.e000563.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2015.04.005"},{"key":"2025083110412171000_7.1.e000563.35","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-10-201205150-00004"},{"key":"2025083110412171000_7.1.e000563.36","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-019-0880-0","article-title":"Acute exacerbation of chronic fibrosing interstitial pneumonia in patients receiving antifibrotic agents: incidence and risk factors from real-world experience","volume":"19","author":"Kawamura","year":"2019","journal-title":"BMC Pulm Med"},{"key":"2025083110412171000_7.1.e000563.37","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-016-0400-1","article-title":"Risk factors for an acute exacerbation of idiopathic pulmonary fibrosis","volume":"17","author":"Kakugawa","year":"2016","journal-title":"Respir Res"},{"key":"2025083110412171000_7.1.e000563.38","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2169\/internalmedicine.9331-17","article-title":"Prognostic factors in the acute exacerbation of idiopathic pulmonary fibrosis: a retrospective single-center study","volume":"57","author":"Atsumi","year":"2018","journal-title":"Intern. Med."},{"key":"2025083110412171000_7.1.e000563.39","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2009-040GL"},{"key":"2025083110412171000_7.1.e000563.40","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-019-1161-4","article-title":"Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat","volume":"20","author":"Maher","year":"2019","journal-title":"Respir Res"},{"key":"2025083110412171000_7.1.e000563.41","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211448"},{"key":"2025083110412171000_7.1.e000563.42","doi-asserted-by":"publisher","DOI":"10.1002\/art.27405"},{"key":"2025083110412171000_7.1.e000563.43","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00092309"},{"key":"2025083110412171000_7.1.e000563.44","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00357-2015"},{"key":"2025083110412171000_7.1.e000563.45","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1513\/AnnalsATS.201704-288OC","article-title":"Epidemiology of hypersensitivity pneumonitis among an insured population in the United States: a claims-based cohort analysis","volume":"15","author":"Fern\u00e1ndez P\u00e9rez","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"2025083110412171000_7.1.e000563.46","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00158507"},{"key":"2025083110412171000_7.1.e000563.47","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1513\/AnnalsATS.201801-067OC","article-title":"Heterogeneity in unclassifiable interstitial lung disease. A systematic review and meta-analysis","volume":"15","author":"Guler","year":"2018","journal-title":"Ann Am Thorac Soc"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2020-000563","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T17:41:29Z","timestamp":1756662089000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2020-000563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,4,6]]},"published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1136\/bmjresp-2020-000563"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2020-000563","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}